143B m.8993T>G isogenic mTUNE mT70 Cell Line

Exclusive tool

Contributors

Inventor Institute
Payam Gammage Cancer Research UK, Glasgow: The Beatson Institute
SKU: 160451
Product description: The cellular metabolic environemnt is influenced by relative levels of coexistant mutant and wild-type mitochondrial DNAs (heteorplasmy) in a range of diseases for which mitochondrial dysfunction is a feature. Disease phenotypes may be rescued by returning heteroplasmy towards wild-type levels. To investigate this approach, the team led by Payam Gammage have devised a series of cell lines which stably express stable levels of mutatnt m.8993T>G mtDNA heteroplasmy. Cell lines bearing m.8993T>G heteroplasmy of 70 and 10% are available at CancerTools.org. These lines are derivatives of the m.8993T cybrid cell developed by Prof Eric Schon, and are of of 143B human osteosarcoma lineage. This is part of a series of two cell line (mTUNE); see Related research tools tab.
Alternate name: mTUNE 7, mT7
Production details: mTUNE cells were generated by Dr Michal Minczukâ?‚€?‚™s lab and derive from female human osteosarcoma 143B (RRID: CVCL_2270) cybrid cells (Porteous et al., 1998), after correction of m.8993T>G mutation with mitochondrially-targeted zinc finger nucleases (Gammage et al., 2016a). See Gaude et al., 2018 for further details.
Additional notes: This is part of a series of two cell line (mTUNE); see Related Reagents tab.
Parental cell line: 143B human osteosarcoma (m.8993T>G cybrid)
Disease: Cancer
Cat. #: 160451
Provenance and Ownership: The 143B m.8993T>G isogenic mTUNE mT70 Cell Line is owned by Cancer Research UK. CancerTools supplies the 143B m.8993T>G isogenic mTUNE mT70 Cell Line under licence from Cancer Research UK and is the authorised source for its distribution. Sourcing 143B m.8993T>G isogenic mTUNE mT70 Cell Line directly from the IP owner ensures authenticity, provenance and compliance with all applicable licensing and research use requirements.
Tool sub type: Continuous
Unit size: 1×10^6 cells / vial
Organism: Human
Tissue: Bone
Model: Tumour line
Format: Frozen
Shipping conditions: Dry ice
Growth medium: high glucose DMEM media supplemented with L-glutamine and 10S and pen/strep
Subculture routine: Grow in regular dishes or flasks (10cm dish or 75cm2 flask). Passage 2 or 3 times a week, split when confluent (wash with PBS and then use trypsin to split). There is no maximum passage number. 1:10 for 3 splits a week, 1:20 Friday to Monday
References:

Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo.

Enhanced Manipulation of Human Mitochondrial DNA Heteroplasmy In Vitro Using Tunable mtZFN Technology.

NADH Shuttling Couples Cytosolic Reductive Carboxylation of Glutamine with Glycolysis in Cells with Mitochondrial Dysfunction.

Engineered mtZFNs for Manipulation of Human Mitochondrial DNA Heteroplasmy.

Near-complete elimination of mutant mtDNA by iterative or dynamic dose-controlled treatment with mtZFNs….

Images

View Gallery
Gaude et al.; 2018. DOI

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.